Thromb Haemost 1969; 21(01): 346-353
DOI: 10.1055/s-0038-1653544
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

Platelet Changes Induced by Elatericin A

H Joshua
1  Department of Pharmacology, Tel-Aviv University Medical School, The Rogoff-Wellcome Medical Research Institute, and the Clinical Laboratory, Beilinson Hospital, Petah-Tikva
,
B Shohat
1  Department of Pharmacology, Tel-Aviv University Medical School, The Rogoff-Wellcome Medical Research Institute, and the Clinical Laboratory, Beilinson Hospital, Petah-Tikva
,
I Cohen
1  Department of Pharmacology, Tel-Aviv University Medical School, The Rogoff-Wellcome Medical Research Institute, and the Clinical Laboratory, Beilinson Hospital, Petah-Tikva
,
S Gitter
1  Department of Pharmacology, Tel-Aviv University Medical School, The Rogoff-Wellcome Medical Research Institute, and the Clinical Laboratory, Beilinson Hospital, Petah-Tikva
› Author Affiliations
Further Information

Publication History

Publication Date:
10 June 2018 (online)

Summary

Elatericin A at a concentration of 3 μg/ml causes spicule formation on platelets and inhibits spreading on glass surfaces, viscous metamorphosis and clot retraction. Elatericin A has no effect whatsoever on the activity of isolated platelet factors. However platelet factor 3-availability is decreased by elatericin A. Platelets treated with elatericin A up to a limiting concentration of 30 μg/ml regain their clot retracting activity if washed and reincubated in normal plasma.

Elatericin A does not affect the ATP content nor the ATPase activity of platelets. A normal ADP-release is obtained upon addition of thrombin to elatericin A treated platelets. Addition of ATP and Mg ions does not restore the clot retracting activity of elatericin A treated platelets.